Attached files

file filename
EX-31.2 - EX-31.2 - SYNAGEVA BIOPHARMA CORPd856934dex312.htm
EX-31.1 - EX-31.1 - SYNAGEVA BIOPHARMA CORPd856934dex311.htm
EX-21.1 - EX-21.1 - SYNAGEVA BIOPHARMA CORPd856934dex211.htm
EX-23.1 - EX-23.1 - SYNAGEVA BIOPHARMA CORPd856934dex231.htm
EX-10.19 - EX-10.19 - SYNAGEVA BIOPHARMA CORPd856934dex1019.htm
EXCEL - IDEA: XBRL DOCUMENT - SYNAGEVA BIOPHARMA CORPFinancial_Report.xls
10-K - FORM 10-K - SYNAGEVA BIOPHARMA CORPd856934d10k.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002*

Pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned, as principal executive officer and principal financial officer of Synageva BioPharma Corp. (the “Company”), does hereby certify that to such officer’s knowledge:

(1) the Company’s Form 10-K for the period ended December 31, 2014 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Company’s Form 10-K for the period ended December 31, 2014 fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Sanj K. Patel

Sanj K. Patel
President and Chief Executive Officer

/s/ Carsten Boess

Carsten Boess
Senior Vice President, Chief Financial Officer
Date: February 26, 2015

 

* A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Synageva BioPharma Corp. and will be retained by Synageva BioPharma Corp. and provided to the Securities and Exchange Commission or its staff upon request.